James N Gerson
Overview
Explore the profile of James N Gerson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas C, Porter D, Van Deerlin V, Bhattacharyya S, Carvajal V, Kim J, et al.
Leuk Lymphoma
. 2025 Feb;
:1-4.
PMID: 39921538
No abstract available.
2.
Shah N, Wang M, Roeker L, Patel K, Woyach J, Wierda W, et al.
Haematologica
. 2024 Oct;
110(1):92-102.
PMID: 39363864
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase I/II BRUIN study evaluated pirtobrutinib, a highly selective...
3.
Chong E, Kumashie K, Chong E, Fabrizio J, Gupta A, Svoboda J, et al.
J Infect Dis
. 2024 Jul;
230(1):15-27.
PMID: 39052709
Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. Severe acute respiratory...
4.
Bhansali R, Ellin F, Relander T, Cao M, Li W, Long Q, et al.
Blood Adv
. 2024 May;
8(13):3507-3518.
PMID: 38739715
Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS...
5.
Chong E, Chong E, Therwhanger D, Nasta S, Landsburg D, Barta S, et al.
Transplant Cell Ther
. 2024 Mar;
30(7):726.e1-726.e8.
PMID: 38494076
Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory mantle cell lymphoma (MCL). During a fludarabine shortage, we used bendamustine as...
6.
Ghilardi G, Fraietta J, Gerson J, Van Deerlin V, Morrissette J, Caponetti G, et al.
Nat Med
. 2024 Jan;
30(4):984-989.
PMID: 38266761
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a...
7.
Ghilardi G, Paruzzo L, Svoboda J, Chong E, Shestov A, Chen L, et al.
Blood Adv
. 2023 Dec;
8(3):653-666.
PMID: 38113468
Lymphodepletion (LD) is an integral component of chimeric antigen receptor T-cell (CART) immunotherapies. In this study, we compared the safety and efficacy of bendamustine (Benda) to standard fludarabine/cyclophosphamide (Flu/Cy) LD...
8.
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al.
Blood Adv
. 2023 Oct;
7(24):7393-7401.
PMID: 37874912
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants...
9.
Mato A, Woyach J, Brown J, Ghia P, Patel K, Eyre T, et al.
N Engl J Med
. 2023 Jul;
389(1):33-44.
PMID: 37407001
Background: Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options...
10.
Landsburg D, Nasta S, Svoboda J, Gerson J, Schuster S, Barta S, et al.
Transplant Cell Ther
. 2023 May;
29(8):495-503.
PMID: 37211154
Patients diagnosed with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL) may achieve prolonged survival following receipt of high-dose chemotherapy/autologous stem cell transplantation (HDC/ASCT)...